Top

Sleep and Breathing

Published in:

01-12-2019 | Sleep Apnea | Sleep Breathing Physiology and Disorders • Original Article

Sleep apnea and galectin-3: possible sex-specific relationship

Authors: Mohita Singh, Craig L. Hanis, Susan Redline, Christie M. Ballantyne, Ihab Hamzeh, David Aguilar

Published in: Sleep and Breathing | Issue 4/2019

Abstract

Purpose

Sleep apnea is associated with increased risk of cardiovascular disease. Elevated plasma galectin-3 levels, a biomarker associated with myocardial fibrosis, are also associated with adverse cardiovascular events, including heart failure. Our objective was to determine the relationship between severity of sleep apnea and plasma levels of galectin-3 and to determine whether this relationship was modified by sex.

Methods

We performed a cross-sectional study of 471 Mexican Americans from Starr County, TX who underwent an overnight, in-home sleep evaluation, and plasma measurement of galectin-3. Severity of sleep apnea was based on apnea hypopnea index (AHI). Multivariable linear regression modeling was used to determine the association between categories of sleep apnea and galectin-3. We also tested for interactions by sex.

Results

The mean age was 53 years, and 74% of the cohort was female. The prevalence of moderate to severe sleep apnea (AHI > 15 apnea–hypopnea events per hour) was 36.7%. Moderate to severe sleep apnea was associated with increased levels of galectin-3 in the entire population, but we identified a statistically significant interaction between galectin-3 levels and category of sleep apnea by sex (p for interaction = 0.02). Plasma galectin levels were significantly higher in women with moderate or severe sleep apnea than women with no/mild sleep apnea (multivariable adjusted p < 0.001), but not in men (p = 0.5).

Conclusions

Sleep apnea is associated elevated galectin-3 levels in women but not men. Our findings highlight a possible sex-specific relationship between sleep apnea and galectin-3, a biomarker of potential myocardial fibrosis that has been associated with increased cardiovascular risk.

Suthahar N, Meijers WC, Sillje HHW, Ho JE, Liu FT, de Boer RA (2018) Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics 8(3):593–609. https://doi.org/10.7150/thno.22196 CrossRefPubMedPubMedCentral

Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA (2015) Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta 443:48–56. https://doi.org/10.1016/j.cca.2014.10.009 CrossRefPubMed

Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM (2004) Galectin-3 marks activated macrophages in failure-prone hyspertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19):3121–3128. https://doi.org/10.1161/01.CIR.0000147181.65298.4D CrossRefPubMed

Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E (2014) Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study. Am Heart J 167(5):674–682 e671. https://doi.org/10.1016/j.ahj.2013.12.031 CrossRefPubMedPubMedCentral

Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60(14):1249–1256. https://doi.org/10.1016/j.jacc.2012.04.053 CrossRefPubMedPubMedCentral

de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P (2012) The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272(1):55–64. https://doi.org/10.1111/j.1365-2796.2011.02476.x CrossRefPubMed

Djousse L, Matsumoto C, Petrone A, Weir NL, Tsai MY, Gaziano JM (2014) Plasma galectin 3 and heart failure risk in the Physicians’ Health Study. Eur J Heart Fail 16(3):350–354. https://doi.org/10.1002/ejhf.21 CrossRefPubMed

Jagodzinski A, Havulinna AS, Appelbaum S, Zeller T, Jousilahti P, Skytte-Johanssen S, Hughes MF, Blankenberg S, Salomaa V (2015) Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int J Cardiol 192:33–39. https://doi.org/10.1016/j.ijcard.2015.05.040 CrossRefPubMed

Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, O’Connor GT, Boland LL, Schwartz JE, Samet JM (2001) Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163(1):19–25. https://doi.org/10.1164/ajrccm.163.1.2001008 CrossRefPubMed

10.

Cadby G, McArdle N, Briffa T, Hillman DR, Simpson L, Knuiman M, Hung J (2015) Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest 148(4):945–952. https://doi.org/10.1378/chest.15-0229 CrossRefPubMed

11.

Gottlieb DJ, Yenokyan G, Newman AB, O’Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E (2010) Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 122(4):352–360. https://doi.org/10.1161/CIRCULATIONAHA.109.901801 CrossRefPubMedPubMedCentral

12.

Cowie MR (2017) Sleep apnea: state of the art. Trends Cardiovasc Med 27(4):280–289. https://doi.org/10.1016/j.tcm.2016.12.005 CrossRefPubMed

13.

Querejeta Roca G, Redline S, Punjabi N, Claggett B, Ballantyne CM, Solomon SD, Shah AM (2013) Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med 188(12):1460–1465. https://doi.org/10.1164/rccm.201309-1572OC CrossRefPubMed

14.

Roca GQ, Redline S, Claggett B, Bello N, Ballantyne CM, Solomon SD, Shah AM (2015) Sex-specific association of sleep apnea severity with subclinical myocardial injury, ventricular hypertrophy, and heart failure risk in a community-dwelling cohort: the atherosclerosis risk in communities-sleep heart health study. Circulation 132(14):1329–1337. https://doi.org/10.1161/CIRCULATIONAHA.115.016985 CrossRefPubMedPubMedCentral

15.

Randby A, Namtvedt SK, Einvik G, Hrubos-Strom H, Hagve TA, Somers VK, Omland T (2012) Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels. Chest 142(3):639–646. https://doi.org/10.1378/chest.11-1779 CrossRefPubMed

16.

Ljunggren M, Lindahl B, Theorell-Haglow J, Lindberg E (2012) Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women. Sleep 35(11):1521–1527. https://doi.org/10.5665/sleep.2202 CrossRefPubMedPubMedCentral

17.

Redline S, Sotres-Alvarez D, Loredo J, Hall M, Patel SR, Ramos A, Shah N, Ries A, Arens R, Barnhart J, Youngblood M, Zee P, Daviglus ML (2014) Sleep-disordered breathing in Hispanic/Latino individuals of diverse backgrounds. The Hispanic Community Health Study/Study of Latinos. Am J Respir Crit Care Med 189(3):335–344. https://doi.org/10.1164/rccm.201309-1735OC CrossRefPubMedPubMedCentral

18.

Young T, Finn L (1998) Epidemiological insights into the public health burden of sleep disordered breathing: sex differences in survival among sleep clinic patients. Thorax 53(Suppl 3):S16–S19CrossRefPubMedPubMedCentral

19.

Bureau USC Quick Facts: Starr County Texas. http://www.census.gov/quickfacts/table/PST045215/48427. Accessed September 4 2016

20.

Hanis CL, Redline S, Cade BE, Bell GI, Cox NJ, Below JE, Brown EL, Aguilar D (2016) Beyond type 2 diabetes, obesity and hypertension: an axis including sleep apnea, left ventricular hypertrophy, endothelial dysfunction, and aortic stiffness among Mexican Americans in Starr County, Texas. Cardiovasc Diabetol 15:86. https://doi.org/10.1186/s12933-016-0405-6 CrossRefPubMedPubMedCentral

21.

Yalamanchali S, Farajian V, Hamilton C, Pott TR, Samuelson CG, Friedman M (2013) Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-analysis. JAMA Otolaryngol Head Neck Surg 139(12):1343–1350. https://doi.org/10.1001/jamaoto.2013.5338 CrossRefPubMed

22.

Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, Srinivas PR, Deswal A, Mosley TH, Coresh J, Folsom AR, Heiss G, Ballantyne CM (2013) Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. Clin Chem 59(12):1802–1810. https://doi.org/10.1373/clinchem.2013.203638 CrossRefPubMedPubMedCentral

23.

deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL (2010) Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304(22):2494–2502. https://doi.org/10.1001/jama.2010.1708 CrossRefPubMedPubMedCentral

24.

Hill SA, Balion CM, Santaguida P, McQueen MJ, Ismaila AS, Reichert SM, McKelvie R, Worster A, Raina PS (2008) Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. Clin Biochem 41(4–5):240–249. https://doi.org/10.1016/j.clinbiochem.2007.08.016 CrossRefPubMed

25.

Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM (2011) Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 123(13):1367–1376. https://doi.org/10.1161/CIRCULATIONAHA.110.005264 CrossRefPubMedPubMedCentral

26.

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350(7):655–663. https://doi.org/10.1056/NEJMoa031994 CrossRefPubMed

27.

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, Lopez-Andres N (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33(1):67–75. https://doi.org/10.1161/ATVBAHA.112.300569 CrossRefPubMed

28.

Vergaro G, Prud’homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A, Delcayre C (2016) Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension 67(3):606–612. https://doi.org/10.1161/HYPERTENSIONAHA.115.06161 CrossRefPubMed

29.

Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Sillje HH, de Boer RA (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6(1):107–117. https://doi.org/10.1161/CIRCHEARTFAILURE.112.971168 CrossRefPubMed

30.

Peppard PE, Young T, Palta M, Skatrud J (2000) Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342(19):1378–1384. https://doi.org/10.1056/NEJM200005113421901 CrossRefPubMed

31.

Otto ME, Belohlavek M, Romero-Corral A, Gami AS, Gilman G, Svatikova A, Amin RS, Lopez-Jimenez F, Khandheria BK, Somers VK (2007) Comparison of cardiac structural and functional changes in obese otherwise healthy adults with versus without obstructive sleep apnea. Am J Cardiol 99(9):1298–1302. https://doi.org/10.1016/j.amjcard.2006.12.052 CrossRefPubMed

32.

Chami HA, Devereux RB, Gottdiener JS, Mehra R, Roman MJ, Benjamin EJ, Gottlieb DJ (2008) Left ventricular morphology and systolic function in sleep-disordered breathing: the Sleep Heart Health Study. Circulation 117(20):2599–2607. https://doi.org/10.1161/CIRCULATIONAHA.107.717892 CrossRefPubMedPubMedCentral

33.

Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, Malhotra A, Martinez-Garcia MA, Mehra R, Pack AI, Polotsky VY, Redline S, Somers VK (2017) Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol 69(7):841–858. https://doi.org/10.1016/j.jacc.2016.11.069 CrossRefPubMedPubMedCentral

34.

Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, Initiative I (2017) Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. Circulation 136(19):1840–1850. https://doi.org/10.1161/CIRCULATIONAHA.117.029400 CrossRefPubMedPubMedCentral

35.

Chen TI, Tu WC (2016) Exercise attenuates intermittent hypoxia-induced cardiac fibrosis associated with sodium-hydrogen exchanger-1 in rats. Front Physiol 7:462. https://doi.org/10.3389/fphys.2016.00462 CrossRefPubMedPubMedCentral

36.

Ding WX, Dong YB, Ding N, Zhang XF, Zhang SJ, Zhang XL, Liu JN, Lu G (2014) Adiponectin protects rat heart from left ventricular remodeling induced by chronic intermittent hypoxia via inhibition of TGF-beta/smad2/3 pathway. J Thorac Dis 6(9):1278–1284. https://doi.org/10.3978/j.issn.2072-1439.2014.07.44 CrossRefPubMedPubMedCentral

37.

Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O’Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM (2009) Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 6(8):e1000132. https://doi.org/10.1371/journal.pmed.1000132 CrossRefPubMedPubMedCentral

38.

Faulx MD, Larkin EK, Hoit BD, Aylor JE, Wright AT, Redline S (2004) Sex influences endothelial function in sleep-disordered breathing. Sleep 27(6):1113–1120CrossRefPubMed

39.

Chew M, Xie J, Klein R, Klein B, Cotch MF, Redline S, Wong TY, Cheung N (2016) Sleep apnea and retinal signs in cardiovascular disease: the multi-ethnic study of atherosclerosis. Sleep Breath 20(1):15–23. https://doi.org/10.1007/s11325-015-1177-z CrossRefPubMed

40.

Macey PM, Kumar R, Woo MA, Yan-Go FL, Harper RM (2013) Heart rate responses to autonomic challenges in obstructive sleep apnea. PLoS One 8(10):e76631. https://doi.org/10.1371/journal.pone.0076631 CrossRefPubMedPubMedCentral

41.

McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS, Investigators S, Coordinators (2016) CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 375(10):919–931. https://doi.org/10.1056/NEJMoa1606599 CrossRefPubMed

42.

Foster GD, Sanders MH, Millman R, Zammit G, Borradaile KE, Newman AB, Wadden TA, Kelley D, Wing RR, Sunyer FX, Darcey V, Kuna ST, Sleep ARG (2009) Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 32(6):1017–1019. https://doi.org/10.2337/dc08-1776 CrossRefPubMedPubMedCentral

Title: Sleep apnea and galectin-3: possible sex-specific relationship
Authors: Mohita Singh
Craig L. Hanis
Susan Redline
Christie M. Ballantyne
Ihab Hamzeh
David Aguilar
Publication date: 01-12-2019
Publisher: Springer International Publishing
Keywords: Sleep Apnea
Heart Failure
Published in: Sleep and Breathing / Issue 4/2019
Print ISSN: 1520-9512
Electronic ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-019-01788-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

In memoriam Christian Guilleminault (1938–2019)

The reduction of apnea–hypopnea duration ameliorates endothelial dysfunction, vascular inflammation, and systemic hypertension in a rat model of obstructive sleep apnea

Comorbidities associated with obstructive sleep apnea: a retrospective Egyptian study on 244 patients

Association of continuous positive airway pressure with F2-isoprostanes in adults with obstructive sleep apnea: a meta-analysis

Real-world STOPBANG: how useful is STOPBANG for sleep clinics?

Prophylactic use of exogenous melatonin and melatonin receptor agonists to improve sleep and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage